Cefepime and Enmetazobactam Injection (Exblifep)

The U.S. Food and Drug Administration has approved the combination of cefepime and enmetazobactam (FPE) for the treatment of complicated urinary tract infections. Cefepime-enmetazobactam was granted a priority review and a five-year marketing exclusivity as part of the Generating Antibiotic Incentive Now (GAIN) Act incentivizing development of new anti-infectives. FPE is distributed by Allecra Therapeutics SAS as Exblifep.